Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992573 | 1.00 | KCNN4 (0.43) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL992574 | 1.00 | KCNN4 (0.43) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL6036541 | 0.89 | KIF11 (0.39) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL29276034 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL26062663 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL31696759 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL5200976 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL3548775 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL3548773 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL6399801 | 0.86 | NR1H2 (0.46) | MMP2ANPEPCYP1A2CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| CN-109928971-B | Aryl substituted aminotetrahydropyrans and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023107487-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-8030315-B2 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity | DONG-A PHARM. CO., LTD. (KR) | 2011-10-04 | — | — | US | disclosed |
| US-8030315-B2 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity | DONG-A PHARM. CO., LTD. (KR) | 2011-10-04 | — | — | US | disclosed |
| US-20110201624-A1 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2011-08-18 | — | — | US | disclosed |
| EP-2351567-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | Dong-A Pharmaceutical Co., Ltd. (KR) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010114291-A2 | IMPROVED METHOD FOR PREPARING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | 동아제약 주식회사 (KR) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114292-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | 동아제약 주식회사 (KR) | 2010-10-07 | — | — | WO | disclosed |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DONG-A PHARM. CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DONG-A PHARM. CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
| EP-2142519-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | Dong-A Pharm.Co., Ltd. (KR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130151-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG-A PHARM. CO., LTD. (KR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KCNN4 1068/4885MMP2 2612/4885KMT2A 4648/4885 |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DPP4, DPP7, DPP3 | KCNN4 1829/4885MMP2 66/4885KMT2A 1753/4885 |
| US-20110201624-A1 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients | DPP4, DPP3, DPP7 | KCNN4 2096/4885MMP2 26/4885KMT2A 2190/4885 |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KCNN4 1001/4885MMP2 2673/4885KMT2A 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.